A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Inclusion Criteria: * ECOG Performance Status of 0-1. * Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression). * Tumor stage: II-III. * Adequate hematologic and organ function. * Must be willing to use an adequate method of contraception for the course of the study. Exclusion Criteria: * Has a history of breast cancer. * Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months. * Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\]. * Has a diagnosis of immunodeficiency or autoimmune diseases. * Has received any form of immunosuppressive therapy within 4 weeks prior to the first dose of study treatment. * Severe pulmonary or cardiac disease. * Known active hepatitis C virus, or known active hepatitis B virus. * History of organ or bone marrow transplantation. * Pregnant or breast-feeding women.